Enanta Pharmaceuticals Inc

NASDAQ:ENTA   3:59:59 PM EDT
38.13
-0.59 (-1.52%)
Products

Enanta Pharmaceuticals Receives FDA Fast Track Designation For EDP-235, Its Oral 3Cl Protease Inhibitor To Treat And Prevent Covid-19

Published: 03/29/2022 11:23 GMT
Enanta Pharmaceuticals Inc (ENTA) - Enanta Pharmaceuticals Receives FDA Fast Track Designation for Edp-235, Its Oral 3cl Protease Inhibitor Specifically Designed for the Treatment and Prevention of Covid-19.
Enanta Pharmaceuticals Receives FDA Fast Track Designation for Edp-235, Its Oral 3cl Protease Inhibitor Specifically Designed for the Treatment and Prevention of Covid-19.